Pipeline Close TAKEDA In 2008, Domain Therapeutics signed a research agreement with Takeda Pharmaceutical Company Limited (Tokyo, Japan) Under the agreement, Domain Therapeutics applied its DTect-All™ platform to identify novel drug candidates that target undisclosed G Protein-Coupled Receptors (GPCRs) of interest to Takeda. In 2009 Domain Therapeutics announced that it has successfully completed the first milestone in this research agreement with Takeda Pharmaceutical. Following milestone completion have not been publicly announced. Pipeline Partnering Opportunities Resources Careers Contact us 77/100 2021 #Discovermorethanyouthink Strasbourg - Illkirch Domain Therapeutics SA Bioparc 1 - 850 Boulevard Sébastien Brant 67400 Strasbourg - Illkirch - France https://www.domaintherapeutics.com/ Montreal Domain Therapeutics NA Inc. Neomed Institute - 7171 Frédérick Banting H4S 1Z9 Montreal - Canada https://www.domaintherapeutics.ca/ © 2021 Domain Therapeutics - All rights reserved Privacy Legal notices RSS Axeptio consent